Nanatinostat

Product Description

Nanatinostat (VRx-3996) is an orally available histone deacetylase (HDAC) inhibitor being developed by Viracta. Nanatinostat is selective for specific isoforms of Class I HDACs, which is key to inducing viral genes that are epigenetically silenced in EBV-associated malignancies. Nana-val (nanatinostat and valganciclovir) is being investigated in multiple subtypes of relapsed/refractory EBV+ lymphoma and in advanced EBV+ solid tumors in three ongoing trials, one of which is a registration-enabling global, multicenter, open-label Phase 2 basket trial in relapsed/refractory EBV+ lymphoma (NAVAL-1). (Sourced from: https://viracta.investorroom.com/2021-11-29-Viracta-Therapeutics-Announces-Orphan-Drug-Designation-Granted-by-FDA-for-its-All-Oral-Combination-of-Nanatinostat-and-Valganciclovir-Nana-val-for-the-Treatment-of-Epstein-Barr-Virus-Positive-Diffuse-Large-B-cell-Lymphoma)

Mechanisms of Action: HDAC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation:
Orphan Drug - Diffuse Large B-Cell Lymphoma|Lymphoma|Lymphoma, B-Cell
Orphan Drug - Lymphoma|T-Cell Lymphoma
Orphan Drug - Lymphoma|T-Cell Lymphoma|T-Cell Peripheral Lymphoma
Orphan Drug - Nasopharyngeal Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Viracta Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None